{"id":"augmenting-antidepressant-bupropion-sr","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Agitation"},{"rate":"0.4","effect":"Seizures (dose-dependent)"}]},"_chembl":{"chemblId":"CHEMBL1201735","moleculeType":"Small molecule","molecularWeight":"320.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination strategy leverages bupropion's unique mechanism as a norepinephrine-dopamine reuptake inhibitor (NDRI) to enhance the effects of serotonergic antidepressants. By adding dopaminergic and noradrenergic activity to existing serotonergic therapy, the augmentation approach targets multiple neurotransmitter systems simultaneously, potentially improving efficacy in treatment-resistant depression. Bupropion-SR (sustained-release) formulation provides steady-state levels suitable for adjunctive use.","oneSentence":"Bupropion-SR augments antidepressant therapy by inhibiting norepinephrine and dopamine reuptake, addressing residual depressive symptoms in patients with incomplete response to initial antidepressant monotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:12.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder with incomplete response to initial antidepressant monotherapy"},{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT01421342","phase":"PHASE3","title":"VA Augmentation and Switching Treatments for Improving Depression Outcomes","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-12","conditions":"Major Depressive Disorder","enrollment":1522}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Augmenting: Antidepressant + Bupropion-SR","genericName":"Augmenting: Antidepressant + Bupropion-SR","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion-SR augments antidepressant therapy by inhibiting norepinephrine and dopamine reuptake, addressing residual depressive symptoms in patients with incomplete response to initial antidepressant monotherapy. Used for Major depressive disorder with incomplete response to initial antidepressant monotherapy, Treatment-resistant depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}